home / stock / alpmy / alpmy articles
- Focuses on digitizing cell manufacturing processes through robotics technology TOKYO, May 21, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 450...
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
- Open Innovation Hub Named SakuLabTM-Tsukuba will open at the Astellas Tsukuba Research Center - TOKYO and BOSTON, Oct. 10, 2023 /PRNewswire/ -- ...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected not to exercise its option to obtain an exclusive license to TSHA-120 unde...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE PR Newswire If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction canc...
Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies PR Newswire - Focuses on digitizing cell manufacturing processes through robotics technology TOKYO ,...
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting PR Newswire 16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO , May 13, 2024 /PRNe...